Clinical and immunogenetic characteristics of European multicase rheumatoid arthritis families


Rheumatology Unit, University Hospital La Paz, 28046 Madrid, Spain
A Balsa
D Pascual-Salcedo

University Hospital, 6500HH Nijmegen, The Netherlands
P Barrera
T R D J Radstake

Katholieke Universiteit Leuven, 3212 Pellenberg, Belgium
R Westhovens
K Maenaut
M Spaepen

Hospital S Joao, 4200 Porto, Portugal
H Alves
G de Almeida
A Lopes-Vaz

Hôpital Lariboisière, 75010 Paris, France
F Cornélis
T Bardin
P Fritz

Généthon, 91902 Evry, France
F Cornélis
J F Prudhomme
P Fritz

Instituto de Patologia Medica, 56126 Pisa, Italy
L Riente
P Migliorini

Laboratoire d’Histocompatibilité, Hospital Saint-Louis, 75010 Paris, France
V Lepage
D Charron

National Tissue Typing Centre, 11527 Athens, Greece
C Stravopoulos

Institut National de la Santé et de la Recherche Médicale E06, 75010 Paris, France
M Martinez

Correspondence to: Dr A Balsa, Rheumatology Unit, University Hospital La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain abalsa@hulp.insalud.es

Accepted 3 October 2000

*See appendix.
Note: the first two authors contributed equally to the writing of this paper.

Abstract

Objective—To describe the characteristics of a new set of European families with affected sib pairs (ASP) collected by the European Consortium on Rheumatoid Arthritis Families (ECRAF) to replicate the results of our first genome scan. Potential gradients for disease severity in Europe and concordance within families were studied.

Patients and methods—From 1996 to 1998 European white families with at least two affected siblings were enrolled in the study. Demographic (sex, age at onset), clinical data (rheumatoid factor (RF), disease duration, erosive disease, extra-articular features (EF)), and HLA-DRB1 oligotyping were analysed.

Results—565 patients with rheumatoid arthritis (RA), belonging to 271 families including 319 affected sib pairs (ASP) were collected. Belgium, France, Italy, the Netherlands, Portugal, and Spain contributed 20, 96, 52, 24, 9, and 70 families, respectively. Sex (78% women), age at onset (mean 44 years), and RF positivity (79%) were similar among the countries. Differences were found in disease duration (11–18 years) and in the prevalence of erosive disease (70–93%), nodules (15–44%), subjective Sjögren’s syndrome (5–35%), and EF (3–16%) (p<0.05 in all cases). A total of 22% RA sibs were shared epitope (SE) negative, whereas 47% and 30% carried one and two SE alleles respectively. Carriage of SE differed widely among countries (p<0.0001): no SE alleles (6–36%), one allele (43–60%), and two alleles (20–39%). SE encoding alleles were mainly DRB1*04 in the Netherlands and Belgium, whereas SE carriage was less common and evenly distributed between DRB1*01, *04, and *10 in Mediterranean countries. No concordance within families was found either in age/ calendar year of onset (intraclass correlation coefficient <0.50) or in clinical and radiological features (κ<0.22).

Conclusions—The differences in RA characteristics between European countries and within families underline the heterogeneity of the disease. No clear gradient of disease severity was seen in Europe.


Rheumatoid arthritis (RA) is a complex multigenic disease characterised by persistent symmetrical synovitis, leading to cartilage and bone destruction. Its cause is not known, but both genetic and environmental factors play a part. Evidence for the genetic contribution to the susceptibility for RA comes from the familial clustering of the disease,1 2 and from studies showing a four- to fivefold increased RA prevalence in monozygotic compared with dizygotic twins.3 4

RA susceptibility is associated with certain class II genes in the major histocompatibility complex encoding for HLA-DR molecules. The HLA genes associated with RA encode a conserved amino acid sequence in the third hypervariable region of the DR β chain referred to as the shared epitope (SE).4 This association shows ethnic and geographical variations.5 RA is strongly associated with DRB1*0401, *0404, and *0408 alleles in northern Europe,6 7 whereas in Greece, Spain, and Italy associations with DRB1*0405, *0101, *0102, and *1001 alleles have been shown.8 9 10 11

HLA class II genes have been estimated to explain only one third of the total genetic contribution to the disease.12 13 The search for additional susceptibility loci in RA and other multigenic diseases has been stimulated by recent advances in molecular biology and automated gene scanning technology. Two basic approaches are being used at present: (a) exclusion mapping using genome-wide scans and large panels of highly polymorphic microsatellites to identify non-random segregation of parental haplotypes between affected sibling pairs (ASP)14 15 and (b) testing for potential candidate genes relevant for disease susceptibility.16

The European Consortium on Rheumatoid Arthritis Families (ECRAF) has performed an initial genome scan on 97 ASP families, which suggested a second RA locus on chromosome 3 and disclosed at least 10 other regions of interest containing new potential RA susceptibility loci.14 These results need to be replicated in additional sets of families. In this paper we describe the demographic and clinical characteristics of a large new set of ASP families collected by the ECRAF for such replication studies. Potential gradients for RA severity in Europe and concordance within families of disease characteristics were assessed in this family set.
Table 1  Demographic, clinical, and immunogenetic characteristics of the patients studied. Data expressed as mean (SD) or percentage as indicated

<table>
<thead>
<tr>
<th></th>
<th>Belgium (n=43)</th>
<th>France (n=199)</th>
<th>Italy (n=107)</th>
<th>Netherlands (n=51)</th>
<th>Portugal (n=20)</th>
<th>Spain (n=144)</th>
<th>Total (n=564)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Families with sibs (n)</td>
<td>20</td>
<td>96</td>
<td>52</td>
<td>24</td>
<td>9</td>
<td>70</td>
<td>271</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>41 (13)</td>
<td>44 (14)</td>
<td>45 (12)</td>
<td>47 (13)</td>
<td>42 (14)</td>
<td>45 (12)</td>
<td>NS</td>
</tr>
<tr>
<td>Calendar year of disease onset</td>
<td>1979 (11)</td>
<td>1979 (11)</td>
<td>1983 (10)</td>
<td>1985 (8)</td>
<td>1981 (8)</td>
<td>1984 (10)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>18 (12)</td>
<td>16 (12)</td>
<td>13 (10)</td>
<td>11 (8)</td>
<td>12 (6)</td>
<td>13 (10)</td>
<td>NS</td>
</tr>
<tr>
<td>Rheumatoid factor positive (%)</td>
<td>37 (86)</td>
<td>129 (76)</td>
<td>76 (72)</td>
<td>38 (70)</td>
<td>16 (80)</td>
<td>123 (86)</td>
<td>NS</td>
</tr>
<tr>
<td>Nodules (%)</td>
<td>19 (44)</td>
<td>30 (19)</td>
<td>28 (27)</td>
<td>19 (18)</td>
<td>17 (35)</td>
<td>15 (54)</td>
<td>NS</td>
</tr>
<tr>
<td>Erosive disease (%)</td>
<td>36 (84)</td>
<td>150 (73)</td>
<td>89 (83)</td>
<td>34 (68)</td>
<td>14 (82)</td>
<td>116 (81)</td>
<td>NS</td>
</tr>
<tr>
<td>Subjective Sjögren’s syndrome (%)</td>
<td>19 (41)</td>
<td>25 (15)</td>
<td>19 (18)</td>
<td>17 (35)</td>
<td>1 (5)</td>
<td>54 (38)</td>
<td>0.004</td>
</tr>
<tr>
<td>Other extra-articular features (%)</td>
<td>7 (17)</td>
<td>6 (4)</td>
<td>15 (14)</td>
<td>2 (4)</td>
<td>1 (5)</td>
<td>4 (3)</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>7 (17)</td>
<td>6 (4)</td>
<td>15 (14)</td>
<td>2 (4)</td>
<td>1 (5)</td>
<td>4 (3)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Erosive disease (%)</td>
<td>40 (93)</td>
<td>142 (83)</td>
<td>71 (70)</td>
<td>38 (78)</td>
<td>16 (84)</td>
<td>111 (81)</td>
<td>NS</td>
</tr>
<tr>
<td>Shared epitope status (%)</td>
<td>37 (86)</td>
<td>129 (76)</td>
<td>76 (72)</td>
<td>38 (70)</td>
<td>16 (80)</td>
<td>123 (86)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>19 (44)</td>
<td>30 (19)</td>
<td>28 (27)</td>
<td>19 (18)</td>
<td>17 (35)</td>
<td>15 (54)</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>7 (17)</td>
<td>6 (4)</td>
<td>15 (14)</td>
<td>2 (4)</td>
<td>1 (5)</td>
<td>4 (3)</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>7 (17)</td>
<td>6 (4)</td>
<td>15 (14)</td>
<td>2 (4)</td>
<td>1 (5)</td>
<td>4 (3)</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Patients and methods
From 1996 to 1998 European white ASP families were gathered in Belgium, France, Italy, the Netherlands, Portugal, and Spain. Candidate families, identified either by attending rheumatologists or self reported after media announcements, had to have at least two sibships fulfilling American College of Rheumatology criteria for RA. The diagnosis was confirmed by one of the rheumatologists participating in the study or by the clinician in charge of the patient.

A database was constructed using clinical and epidemiological data obtained from medical records and radiographs and/or from direct interviews and examination of patients, if needed. The variables studied included sex, age and calendar year at onset, disease duration, rheumatoid factor (RF) status, and presence/absence of erosive disease, nodules, subjective Sjögren’s syndrome, and other extra-articular features (EF), including pericarditis, vasculitis, rheumatoid lung, or mononeuritis. HLA-DRB1 oligotyping was performed by polymerase chain reaction based methods.

STATISTICAL ANALYSIS
Differences among countries were assessed by analysis of variance and χ² test for continuous and categorical variables, respectively. Concordance within families was analysed using a paired Student’s t test and intraclass correlation coefficient for continuous variables and a k test for categorical variables, respectively. In families with more than two affected sibs, a single random ASP was studied to avoid bias towards a greater concordance.

Results
Two hundred and seventy one European ASP families encompassing 565 patients with RA and 267 non-affected sibs were recruited by the ECARF between 1996 and 1998 (table 1). The distribution of families (and affected sibs) by country was as follows: Belgium 20 (43), France 96 (199), Italy 52 (107), Netherlands 24 (51), Portugal 9 (20), and Spain 70 (144). Most families (n=250) had only two affected sibs, but 19 families had three and two families had four affected sibs.

Table 1 shows demographic and clinical characteristics of the patients in the study. Age of onset, sex, and RF positivity were similar among the European countries. None the less we found differences in calendar year of disease onset (later onset in Spain and the Netherlands than in France; F=0.0001), disease duration (longer in Belgium and France than in the Netherlands; F=0.0001), and extra-articular features (p>0.05; >30% in Spain, the Netherlands, and Belgium, >20% in Italy, and >20% in Spain, the Netherlands, and Belgium).

From 1996 to 1998 European white ASP families were gathered in Belgium, France, Italy, the Netherlands, Portugal, and Spain. Candidate families, identified either by attending rheumatologists or self reported after media announcements, had to have at least two sibships fulfilling American College of Rheumatology criteria for RA. The diagnosis was confirmed by one of the rheumatologists participating in the study or by the clinician in charge of the patient.

A database was constructed using clinical and epidemiological data obtained from medical records and radiographs and/or from direct interviews and examination of patients, if needed. The variables studied included sex, age and calendar year at onset, disease duration, rheumatoid factor (RF) status, and presence/absence of erosive disease, nodules, subjective Sjögren’s syndrome, and other extra-articular features (EF), including pericarditis, vasculitis, rheumatoid lung, or mononeuritis. HLA-DRB1 oligotyping was performed by polymerase chain reaction based methods.

STATISTICAL ANALYSIS
Differences among countries were assessed by analysis of variance and χ² test for continuous and categorical variables, respectively. Concordance within families was analysed using a paired Student’s t test and intraclass correlation coefficient for continuous variables and a k test for categorical variables, respectively. In families with more than two affected sibs, a single random ASP was studied to avoid bias towards a greater concordance.

Results
Two hundred and seventy one European ASP families encompassing 565 patients with RA and 267 non-affected sibs were recruited by the ECARF between 1996 and 1998 (table 1). The distribution of families (and affected sibs) by country was as follows: Belgium 20 (43), France 96 (199), Italy 52 (107), Netherlands 24 (51), Portugal 9 (20), and Spain 70 (144). Most families (n=250) had only two affected sibs, but 19 families had three and two families had four affected sibs.

Table 1 shows demographic and clinical characteristics of the patients in the study. Age of onset, sex, and RF positivity were similar among the European countries. None the less we found differences in calendar year of disease onset (later onset in Spain and the Netherlands than in France; F=0.0001), disease duration (longer in Belgium and France than in the Netherlands; F=0.0001), and extra-articular features (p>0.05; >30% in Spain, the Netherlands, and Belgium, >20% in Italy, and >20% in Spain, the Netherlands, and Belgium).

Despite these differences, no clear cut geographical gradient in clinical, biological, or radiological manifestations between northern and southern Europe was seen.

Tables 1 and 2 show the distribution of HLA-DRB1 alleles encoding the SE. A total of 47% and 30% of the patients carried a single and double SE allele respectively, whereas 22% of the RA sibs were SE negative.

Large differences in SE carriage and in the distribution of alleles were seen among the countries (p=0.0001). SE negative patients were more rare in the Netherlands and Belgium (6% and 12%, respectively) than in Mediterranean countries and Portugal (20–36%). Altogether, HLA-DRB1*04 and 0101 alleles were most prevalent (41% and 22% respectively) and *0405, *0408, and *0102 less frequent (<8%). In the Netherlands and Belgium SE encoding alleles were predominantly DR*04 (81% and 88% respectively), whereas in the other countries the distribution in DR*04, *01, and *10 was more even.
Table 2  Distribution of HLA-DRB1 alleles in ECRAF countries. Data expressed as number and percentage of alleles. For shared epitope (SE) as number and percentage of subjects

<table>
<thead>
<tr>
<th>Country</th>
<th>*0101</th>
<th>*0102</th>
<th>*0401</th>
<th>*0404</th>
<th>*0405</th>
<th>*0408</th>
<th>*1001</th>
<th>SE positive</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
<td>No %</td>
</tr>
<tr>
<td>Belgium</td>
<td>5  10</td>
<td>—</td>
<td>32</td>
<td>8</td>
<td>16</td>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>France</td>
<td>49</td>
<td>21.7</td>
<td>7</td>
<td>3.1</td>
<td>101</td>
<td>33</td>
<td>13.7</td>
<td>6</td>
</tr>
<tr>
<td>Italy</td>
<td>27</td>
<td>30.7</td>
<td>2</td>
<td>2.3</td>
<td>13</td>
<td>14.8</td>
<td>19</td>
<td>21.6</td>
</tr>
<tr>
<td>Netherlands</td>
<td>9</td>
<td>13.2</td>
<td>—</td>
<td>—</td>
<td>41</td>
<td>60.3</td>
<td>9</td>
<td>13.2</td>
</tr>
<tr>
<td>Portugal</td>
<td>7</td>
<td>31.8</td>
<td>—</td>
<td>—</td>
<td>10</td>
<td>45.5</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Spain</td>
<td>34</td>
<td>22.1</td>
<td>13</td>
<td>8.4</td>
<td>49</td>
<td>31.8</td>
<td>12</td>
<td>7.8</td>
</tr>
<tr>
<td>ECRAF</td>
<td>131</td>
<td>21.6</td>
<td>22</td>
<td>3.6</td>
<td>246</td>
<td>40.5</td>
<td>79</td>
<td>13.0</td>
</tr>
</tbody>
</table>

Total number of SE positive alleles was 607. A total of 267 and 170 subjects carried one and two SE positive alleles respectively.

Table 3  Within-family concordance for demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Difference in years (mean (SD))</th>
<th>Intraclass correlation coefficient</th>
<th>Concordance pair (%)</th>
<th>x Value</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset</td>
<td>10 (8)</td>
<td>0.49</td>
<td>0.0</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Calendar year at onset</td>
<td>10 (9)</td>
<td>0.19</td>
<td>0.0</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosive disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodules</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjective Sjögren’s syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other extra-articular features</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To assess the concordance within families, disease characteristics between affected siblings were compared. Differences in age at onset (mean (SD) 10 (8) years) and in calendar year of disease onset (mean (SD) 10 (9) years) between sibs were large (intraclass correlation coefficient <0.5). The concordance for categorical variables such as sex, RF, erosive disease, nodules, Sjögren’s syndrome, and other extra-articular features was also poor (table 3).

Discussion

This study describes a large set of European white ASP families collected by the ECRAF for replication studies. The latter are needed to confirm our initial findings which suggested that besides class II HLA genes, at least 10 different genetic regions may be linked to susceptibility to RA.\(^{14}\) The relative risk of RA among first degree relatives is barely increased compared with that of the general population,\(^ {19}\) and familial aggregation of RA is relatively rare.\(^ {12, 19–21}\) Collection of such a large family set therefore requires international efforts. These offer the opportunity to assess clinical and immunogenetic aspects of the disease in different countries.

Our results show that there is a considerable heterogeneity of RA across Europe. With the exception of age at onset, sex, and RF status, all clinical and radiological variables studied and the results from HLA typing showed a large diversity between European countries. Despite this diversity, we did not see any clear cut gradient in disease severity from northern to southern Europe. Our results, therefore, do not sustain the notion of a mild phenotype of RA in Mediterranean countries\(^ {22, 23}\) compared with a more severe one in northern Europe,\(^ {19, 20}\) though it is possible that our family collection was not big enough to identify this difference.

Phenotypic heterogeneity may, to a certain extent, be explained by genetic factors, including HLA and SE. We found a higher prevalence of SE and double SE alleles in northern European countries. HLA-DRB1*0401 was the most prevalent allele overall, except for Italy, and DRB1*0404 alleles were highly represented in the Netherlands and Belgium. Differences in SE encoding alleles may be relevant as these are not equivalent in prognostic terms. Severe disease has been associated with SE,\(^ {2, 20, 26}\) and with certain DR4 alleles or their combinations,\(^ {25, 28}\) whereas DR1 may be associated with a milder disease course.\(^ {20, 43}\)

From the above mentioned data, it might be expected that RA should be mild in populations with a high prevalence of DR1 and a low prevalence of DR4 alleles, such as Italy, Spain, and Portugal, and more severe in Belgium and the Netherlands, where DR4 is most common. Our results do not support this hypothesis.

The concordance in disease characteristics within affected members of the same family was also studied. This allows some discernment between relative contributions of genes and environment to disease susceptibility. Disease onset tends to occur at a similar age if genetic factors have a major role, but it clusters around the same calendar year if common environmental factors are important. Age, calendar year of onset, and all other clinical and radiological characteristics assessed differed considerably within affected sib pairs in this and previous studies.\(^ {30, 31}\) This emphasises the heterogeneity of the disease even within the same family and may point to a limited role of genetic factors in the susceptibility for RA.

The findings in this study are derived from patients with familial RA and it has been proposed that familial disease may be associated with a more severe disease course.\(^ {1}\) Recent large cross sectional\(^ {23, 23, 3}\) and longitudinal studies\(^ {24}\) in European countries show no relevant differences between familial and sporadic RA, except for the sibship size.\(^ {24}\)

Our findings can therefore be extrapolated to sporadic RA.

Taken together, this study describes the clinical and immunogenetic characteristics of RA in a large set of European families collected by the ECRAF for replication studies on new potential RA loci. Our results show that RA is a heterogeneous disease, not only across Europe but even within affected members of the same family. No evidence for a north to south gradient in disease severity was seen in Europe.

We are indebted to the families and clinicians who participated in the study. The authors thank J Weissenbach and R Madero for their contribution to this study.
Appenleading: Members of the European Consortium on Rheumatoid Arthritis
Families
T. Bardin, D. Charron, F. Cornélis (coordinator), S. Fauré, D. Kunz, M. Martinez, J.P. Prud’homme, J. Weyand (Belgium); B. Lathrop, M. de Rie, L. Nicholls, J. Dequeker, A. Balsa, D. Pascual (Spain); M. Spyropoulou, C. Stravopoulos (Greece); P. Barrera, L.B. van de Putte (The Netherlands); H. Alves, A. Lopes-Vaz (Portugal)


www.annrheumdis.com
Clinical and immunogenetic characteristics of European multicase rheumatoid arthritis families

Ann Rheum Dis 2001 60: 573-576
doi: 10.1136/ard.60.6.573

Updated information and services can be found at:
http://ard.bmj.com/content/60/6/573

These include:
References
This article cites 33 articles, 15 of which you can access for free at:
http://ard.bmj.com/content/60/6/573#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Genetics (968)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/